Addressing COVID-19 vaccine hesitancy
This article seeks to summarize the currently available information to address the most common concerns regarding COVID-19 vaccination.
How COVID-19 shaped mental health: from infection to pandemic effects
The Coronavirus Disease 2019 (COVID-19) pandemic has threatened global mental health, both indirectly via disruptive societal changes and directly via neuropsychiatric sequelae after SARS-CoV-2 infection.
Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return
Due to non-pharmaceutical intervention measures the global influenza burden decreased substantially; but with lifting of restrictions a rebound in other respiratory virus pathogens is both plausible and likely.
Infectious diseases and cognition: do we have to worry?
Age-related physiological changes, particularly immune system decline, may contribute to greater vulnerability to infectious diseases in older individuals.
Older adults and COVID-19 vaccines
What do we know so far about older adults and COVID-19 vaccines? How long does the effect of the vaccine last and how successful have countries been in vaccinating older adults? WHO’s Dr Katherine O’Brien explains in Science in 5
ESWI Young Scientists Network
ESWI launches the call for application for the Claude Hannoun prize for Best Body of Work and the Young Scientist Innovative Award.
|
ESWI Airborne: Meet the Members
Respiratory tract infections in children - our paediatrician's insight and bold vision for the future
Her passion, love and interest to care for children is evident in this personal account by Paula Tähtinen, Clinical Lecturer, Paediatrics and Adolescent Medicine / Adjunct Professor, University of Turku, Finland and ESWI Board Member.
Pandemic Preparedness: Where Science and Policy Meet
Global collaborative response, early warning, One-Health approach, combination of interventions and good communication are key elements for a successful pandemic preparedness instrument
“Flu, COVID and RSV: How to vaccinate?” symposium at Options XI
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
As 2019 turned into 2020, a coronavirus spilled over from wild animals into people, sparking what has become one of the best documented pandemics to afflict humans.
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
The COVID-19 pandemic has been ongoing for more than 2 years now, and new variants such as Omicron are less susceptible to the vaccines developed against earlier lineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.
